Kornimate/medical-research-clean huggingface dataset:
the effect of virtual reality glasses used during burn dressing in children on parents' satisfaction level and anxiety

Conditions: Randomized

Summary: the study was planned as a prospective randomized controlled study and was carried out in the training and research hospital burn unit outpatient clinic between 05.7.2021-1.04.2022. the population of the study consisted of the parents of children aged 5-10 years who applied to the burn unit polyclinic for dressing between the dates of the study. a total of 52 people were included in the research group. data were collected by using the "survey form" consisting of 10 questions, "newcastle nursing satisfaction scale" and "beck anxiety scale".

in this study, the "beck anxiety inventory" was applied to the parents before and after the burn dressing, while the "newcastle satisfaction with nursing scale" was applied only after dressing. control group (n=26): "parent information form" and "beck anxiety inventory" were completed by the researcher nurse after obtaining the consent of the family and the children in the control group. after filling out the form, the parent and child were taken to the dressing room, and the researcher nurse was with both the child and the parent throughout the dressing and answered all the questions that the parent and child had. after the dressing, the child was taken to the waiting room and it was waited for the child to calm down, and "beck anxiety inventory" and "newcastle satisfaction with nursing scale" were applied to the parent by the researcher nurse. the intervention group (n=26): "parent information form" and "beck anxiety inventory" were completed by the researcher nurse after obtaining the consent of the family and the children in the intervention group. then, the parent and child were taken to the dressing room and the child was put on virtual reality headsets and he/she watched a cartoon he/she liked. during this time, all the questions that both the child and the parent had have been answered. after the dressing, the virtual reality headsets were removed, the child was taken to the waiting room and the "beck anxiety inventory" and "newcastle satisfaction with nursing scale" were applied to the parents. during all these processes, procedures were carried out in accordance with the protocols and principles established within the scope of the "covid-19 pandemic measures" published by the ministry of health.

Eligibility criteria:
inclusion criteria: * parents * read and write, * understand turkish, exclusion criteria: * under the age of 18 * do not want to participate in the study * cannot be pregnant
efficacy and safety of ranibizumab in japanese patients with retinal vein occlusion

Conditions: Retinal Vein Occlusion

Summary: the purpose of this study is to provide efficacy and safety data of 3 consecutive monthly intravitreal injections with 0.5 mg ranibizumab in japanese patients with visual impairment due to macular edema secondary to retinal vein occlusion (brvo or crvo) to support the applicability of the phase iii study results of bravo and cruise in this indication, in the japanese ethnic patients.


Eligibility criteria:
inclusion criteria: * japanese patients diagnosed with visual impairment exclusively due to macular edema secondary to either branch retinal vein occlusion (brvo) or central retinal vein occlusion (crvo) diagnosis within 12 months prior to visit 1 * best-corrected visual acuity (bcva): * crvo: bcva score ≥24 and ≤73 letters etdrs (approx. snellen equivalent of 20/320 and 20/40) at visit 1 and 2 * brvo: bcva score ≥19 and ≤73 letters etdrs (approx. snellen equivalent of 20/400 and 20/40) at visit 1 and 2 exclusion criteria: * pregnant or nursing women * history of stroke * uncontrolled blood pressure * active ocular infection or intraocular inflammation in either eye * uncontrolled glaucoma in either eye * neovascularization of the iris or neovascular glaucoma in either eye * prior episode of rvo more than 12 months prior to visit 1 in the study eye * use of any systemic anti-vegf drugs within 6 months prior to visit 2 * prior treatment with any anti-angiogenic drugs within 3 months prior to visit 2 in either eye * prior panretinal laser photocoagulation within 3 months prior to visit 2 in the study eye * prior focal/grid laser photocoagulation within 4 months prior to visit 2 in the study eye * use of intra-/peri-ocular corticosteroids within 3 months prior to visit 1 in the study eye * use of any intra-ocular corticosteroid implants in the study eye other protocol-defined inclusion/exclusion criteria may apply

Keywords: retinal vein occlusion branch retinal vein occlusion central retinal vein occlusion visual impairment macular edema ranibizumab
evaluation of the presence of enthesitis in patients with acne vulgaris

Conditions: Enthesitis; Acne Vulgaris; Ultrasonography

Summary: acne vulgaris is an inflammatory disease of the pilosebaceous unit, affecting about 85% of the young population. in the studies p. acne is a potent stimulator of the release of ifn-gamma (ifn-)) and il-17 from cd4 + t cells, and the presence of il-17 + cells in the perifollicular infiltrate has been shown in biopsies of inflammatory acne lesions. therefore, acne is thought to be a th17-related disease (1). this study was aimed to evaluate the presence of enthesitis in patients with acne vulgaris.

patients with acne vulgaris and healthy controls aged between 18-25 who admitted to hitit university erol olcok education and research hostpital dermatology policlinic will be icluded. patients with rheumatic, neurological diseases, history of trauma and previous fractures will be excluded from the study. after all the participants were evaluated by the dermatologist and demographic data will be recorded, the participants will be examined by the physical medicine and rehabilitation specialist and the short form-36 (sf-36), hospital anxiety and depression scale will be completed. bilateral lower extremity tendon thicknesses and the presence of erosion, bursitis, etc. will be evaluated according to the criteria of guess (glasgow ultrasound enthesitis scoring system) and guess score will be determined for all participants. a total of 48 participants, 24 patients with acne vulgaris and 24 healthy controls, will be included in the study (2).

Eligibility criteria:
inclusion criteira: * patients with acne vulgaris and healthy controls aged between 18-25 exclusion criteria: * participants with rheumatic and neurologic disease, history of trauma ,

Keywords: enthesitis acne vulgaris guess
focus cardiac ultrasound in patients with shock

Conditions: Shock

Summary: the aim of this study is to analyze in patients with undifferentiated shock, the concordance of initial treatment before and after focus cardiac ultrasound (focus) in comparison with the reference one established by an adjudication committee

focus cardiac ultrasound (focus) has already demonstrated its ability to reduce diagnosis uncertainty in patients with undifferentiated shock. however, adequacy of initial treatment has not been investigated. in patients with undifferentiated shock, after clinical evaluation, the physician states its hypothesis and initial treatment intention in closed list. he realizes a focus, states another time the hypothesis and begins treatment according to focus results. an adjudication committee with all the patient's file will state the reference hypothesis and treatment

Eligibility criteria:
inclusion criteria: * undifferentiated shock defined by systolic arterial pressure \< 90 mm hg exclusion criteria: * hemorrhagic shock * cardiac arrest * anaphylactic shock * documented end-of-life

Keywords: shock emergency undifferentiated ultrasound
study evaluating etanercept in patients with rheumatoid arthritis(ra), juvenile idiopathic arthritis (jia), or psoriatic arthritis (psa) in spain

Conditions: Arthritis, Psoriatic; Arthritis, Rheumatoid

Summary: the purpose of this study is to assess the safety of etanercept in patients with rheumatoid arthritis (ra), juvenile idiopathic arthritis (jia) or psoriatic arthritis (psa) in spain


Eligibility criteria:
inclusion criteria: * ra or psa in whom dmards/antitnf antibodies/anti il1 has been insufficient or inappropriate * children from 4 to 17 years old with jia polyarticular exclusion criteria: * clinically significant abnormal screening lab values * patients who are planning to undergo elective surgery during the study period. * other current autoimmune connective tissue diseases
comparison of different peep titration strategies using electrical impedance tomography in patients with ards

Conditions: ARDS (Acute Respiratory Distress Syndrome); Electrical Impedance Tomography (EIT); Positive End Expiratory Pressure (PEEP); Acute Lung Injury

Summary: the aim of the this study is to assess the short term physiological effects of 3 ventilation strategies for adult patients with ards admitted to intensive care unit. two of those strategies are based on electrical impedance tomography (eit) monitoring.


Eligibility criteria:
inclusion criteria: * patients with moderate to severe ards, defined by the berlin consensus, at 12 to 48h from diagnosis * pao2/fio2 ratio \< 150 mmhg * patient affiliated to or beneficiary of a health care plan * consent obtained from patient's sdm exclusion criteria: * pneumothorax * contraindication to the insertion of a nasogastric tube with an esophageal balloon * contraindication to the use of electrical impedance tomography * pregnancy, lactating or parturient woman

Keywords: ards eit peep titration mechanical ventilation
leuplin sr 11.25 mg injection kit specified drug-use survey: "qol survey in premenopausal breast cancer patients"

Conditions: Breast Cancer

Summary: the purpose of this survey is to examine the effect on quality of life (qol) improvement and convenience of switching to leuprorelin acetate 3 months depot 11.25 milligram (mg) injection kit (leuplin sr 11.25 mg injection kit) from a 4-week adjuvant therapy with a luteinizing hormone-releasing hormone analog (lh-rha) 1 month depot over 48 weeks in premenopausal breast cancer participants in daily medical practice. influence of condition of estrogen receptor expression on the efficacy and safety of leuprorelin acetate sr 11.25 mg injection kit was also evaluated.

this survey was designed to examine the effect on qol improvement and convenience of switching to leuprorelin acetate 3 month depot 11.25 mg injection kit (leuplin sr 11.25 mg injection kit) from a 4-week adjuvant therapy with a lh-rha 1 month depot over 48 weeks in premenopausal breast cancer participants in daily medical practice, as well as to evaluate the influence of condition of estrogen receptor expression on the efficacy and safety of leuprorelin acetate sr 11.25 mg injection kit . for adults, leuprorelin acetate sr 11.25 mg injection kit (leuplin sr 11.25 mg injection kit) is usually administered subcutaneously once every 12 weeks. prior to injection, the plunger rod of the syringe is pushed upward with the needle pointed upward, allowing the entire suspension fluid contained to be transferred to the powder. the powder is then fully suspended in the fluid while ensuring that bubbles are not generated.

Eligibility criteria:
inclusion criteria: * premenopausal breast cancer participants who meet all the following criteria are to be enrolled in the surveillance: 1. participants who received 4 weeks of treatment with a repository lh-rha preparation within 1 week prior to administration of leuplin sr 11.25 mg injection kit. 2. participants receiving leuplin sr 11.25 mg injection kit as adjuvant therapy. 3. participants with performance status grade of 0 or 1. 4. participants who answered all of the questions on the "qol check sheet (i)" at the start (week 0) of treatment with leuplin sr 11.25 mg injection kit. exclusion criteria: * participants who meet any of the following criteria are to be excluded from the surveillance: 1. participants with a history of hypersensitivity to ingredient(s) in leuplin sr 11.25 mg injection kit or synthetic derivatives of luteinizing hormone-releasing hormone (lh-rh) or lh-rh. 2. pregnant women, possibly pregnant women, and nursing mothers. 3. participants with advanced (t4 or m1 according to the tnm classification \[general rules for clinical and pathological recording of breast cancer: 16th edition\]) or recurrent breast cancer.

Keywords: pharmacological therapy
reduction of dietary salt intake to control systolic blood pressure in hypertensive older patients

Conditions: Hypertension

Summary: repress is an open label, pragmatic, multicenter, randomized controlled phase iii trial with blinded endpoint with 1:1 (intervention to control arm) allocation ratio. the repress trial is aimed to determine the efficacy of an educational intervention aimed at reducing dietary salt intake in elderly people (60+) with moderate hypertension and exposed to polypharmacy (3+ drugs) in improving systolic bp control compared to an attention arm.


Eligibility criteria:
inclusion criteria: 1. community-dwelling patients aged ≥60 years; 2. prescribed ≥3 drugs; 3. a) systolic blood pressure ≥130 and ≤160 mmhg for patients prescribed stable antihypertensive therapy (at least 1 drug (atc code: c02\*, c03\*, c07\*, c08\*, c09\*)); b) systolic blood pressure ≥140 and ≤160 mmhg for those patients not prescribed any antihypertensive drug; 4. capable of feeding independently; 5. own a smartphone; 6. frequently consuming home-cooked meals (≥4 days during a week and ≥3 during the weekend per month); 7. giving signed informed consent. exclusion criteria: 1. living in a nursing home or having applied for nursing home admission; 2. being prescribed (adding, switching or changing dosage) an antihypertensive drug in the three months before enrollment; 3. undergoing renal replacement therapy with dialysis or having renal impairment with estimated glomerular filtration rate (egfr) \<25 ml/min/1.73 m2 (assessed by ckd-epi formula) \[30\] within previous six months or at the screening assessment; 4. following a low-sodium dietary regimen; 5. being unable or refusing to sign informed consent.

Keywords: randomized controlled trial older patients polypharmacy diet salt intake educational intervention blood pressure
efficacy/ safety of product cm9241gru in patients with perennial allergic rhinitis

Conditions: Rhinitis, Allergic, Perennial

Summary: to evaluate the efficacy and safety of cm9241gru versus placebo in the treatment of perennial allergic rhinitis.


Eligibility criteria:
inclusion criteria: * participants of both sexes aged 18 and over * ability to understand and consent to participate in this clinical research, expressed by signing the informed consent form (icf) * participants with a diagnosis of perennial allergic rhinitis, as determined by a history of symptoms related to non-seasonal allergen exposure for at least 9 months in the 12 months prior to the screening visit. exclusion criteria: * participants who have had nasal surgery in the six (6) months prior to the screening visit, or who have obvious external structural abnormalities that interfere with nasal airflow and are considered clinically relevant by the investigator; * participants with non-allergic rhinitis (e.g. vasomotor, infectious, medication or drug-induced rhinitis) or seasonal allergic rhinitis; * participants with a current diagnosis or history of chronic rhinosinusitis, chronic purulent postnasal drip in the two (2) years prior to the screening visit; * participants diagnosed with asthma requiring regular use of systemic or inhaled corticosteroids; uncontrolled asthma (act: 5-15); partially controlled asthma (act: 16-19); * participants with a history of immunotherapy treatment in the 2 years prior to the screening visit; * participants with an upper respiratory tract infection or rhinosinusitis requiring antibiotic treatment in the 14 days prior to the screening visit and the randomization visit; * participants with an upper respiratory tract viral infection in the 7 days prior to the screening and randomization visits; * participants with severe hypertension, severe coronary artery disease, arrhythmias, glaucoma, hyperthyroidism, prostatic hypertrophy.
evaluating mmps in burns

Conditions: Burns; Thermal Burn; Thermal Injury

Summary: the objective of this study is to determine whether our chemical assay can be used to reliably predict graft take or failure in patients undergoing autologous skin grafting for treatment of acute burn injury.

this is an observational pilot study of patients treated at uf health shands burn center adult service. this is a study to determine the predictive value of quantifying concentrations of specific mmps. coupling this with a specialized collection sample collection system and a calibrated fluorimetry allows for the rapid assessment of mmp concentrations. this assay has been validated as a predictor of failed wound healing in a published clinical study involving chronic open wounds.

Eligibility criteria:
inclusion criteria: * 18 years of age or older * admitted with acute burns injuries (flame, contact or scald) requiring at least one surgical excision and grafting operation will be considered for inclusion * burn injury less than one week old exclusion criteria: * electrical, chemical or cold-induced burn injury * total body surface area burn \>50 % * pre injury diagnosis of chronic renal insufficiency, liver failure, refusal to accept blood transfusion or withdrawal of care within three days of admission will also be exclusion criteria * patients not expected to survive * patients presenting with re-injury to previously burned and treated areas. * patients who present after receiving burn excision surgery out an outside facility for the current acute injury

Keywords: matrix metalloproteinases
effectiveness of enhanced treatments for drug dependence

Conditions: Cocaine Dependence

Summary: the purpose of this challenge grant is to conduct an initial test of a new, enhanced version of this protocol (telephone monitoring and counseling - enhanced, or tmac-e), which has been modified to include the elements of our existing continuing care intervention plus patient-centered changes to boost patient involvement and community linkages. the investigators will recruit 150 cocaine dependent patients in publicly funded, community-based programs and randomize them to treatment as usual or the tmac-e and follow them for 12 months.


Eligibility criteria:
inclusion criteria: * (1) qualify for a dsm-iv diagnosis of cocaine dependence, with some cocaine use in the prior 6 months; * (2) be 18 to 75 years of age; * (3) have no current psychotic disorder or evidence of dementia severe enough to prevent participation in outpatient treatment; * (4) have no acute medical problem requiring immediate inpatient treatment; * (5) not be in methadone or other modes of drug and alcohol treatment, other than intensive outpatient program; * (6) be willing to be randomized and participate in research; * (7) because of study follow-up requirements, subjects will be able to provide the name, verified telephone number, and address of at least one contact who can provide locator information on the patient during follow-up. we will include patients with dependence on other substances, provided that they are cocaine dependent and meet other inclusion criteria. exclusion criteria: * have a current psychotic disorder or evidence of dementia severe enough to prevent participation in outpatient treatment; * have acute medical problem requiring immediate inpatient treatment; * are in methadone or other modes of da treatment, other than iop; * or cannot provide names of people who can get messages to them for follow up, in the event we cannot locate the participant at their original address and number. also, if they are court mandated to treatment or otherwise considered a prisoner, they will be ineligible for the study as we have not applied for subpart c approval.
evaluation of psma-based pet as an imaging biomarker in prostate cancer

Conditions: Advanced Prostate Cancer

Summary: this research is being done to see if an investigational radioactive imaging agent (radiotracer) called 18f-dcfpyl can help us find prostate cancer at its original site in the prostate gland and in distant sites (bone, lymph nodes) in men diagnosed with prostate cancer before surgery.

the investigators propose to evaluate the feasibility of using a novel small molecule pet radiotracer, dcfpyl to target prostate cancer prostate-specific membrane antigen (psma). psma is a well studied cell surface marker of prostate cancer with increased expression associated with higher tumor grade and advanced metastatic tumors. more specifically it is associated with a higher gleason score and there is evidence it can serve as a potential marker for prostate tumor carcinogenesis, progression and as a ar signaling surrogate marker of adt response. this small molecule pet radiotracer specifically targeting an important prostate specific marker of ar signaling dynamics following adt, tumor progression and metastatic potential warrants validation as an in-vivo non-invasive imaging biomarker for psma expression and prostate cancer detection.

Eligibility criteria:
inclusion criteria: * men 18 years of age or greater with recently diagnosed prostate cancer with planned radiation and adt. * key inclusion criteria (the entire list of inclusion and exclusion criteria will appear later in section 4 of the protocol) * newly diagnosed prostate cancer pathologically proven by prostate biopsy * prostate biopsy histology grade ≥ gleason 8-10 * patients considered as candidates for and medically fit to undergo radiation and adt * at least 10 days after most recent prostate biopsy exclusion criteria: * prior pelvic external beam radiation therapy or brachytherapy * chemotherapy for prostate cancer * hormone deprivation therapy * investigational therapy for prostate cancer * hemorrhagic cystitis or active prostatitis

Keywords: radiotracer